Equillium Inc (NASDAQ:EQ) — Market Cap & Net Worth
Market Cap & Net Worth: Equillium Inc (EQ)
Equillium Inc (NASDAQ:EQ) has a market capitalization of $126.05 Million ($126.05 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18287 globally and #4056 in its home market, demonstrating a -4.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Equillium Inc's stock price $2.08 by its total outstanding shares 60893283 (60.89 Million). Analyse EQ cash flow conversion to see how efficiently the company converts income to cash.
Equillium Inc Market Cap History: 2018 to 2026
Equillium Inc's market capitalization history from 2018 to 2026. Data shows change from $496.89 Million to $126.66 Million (-22.30% CAGR).
Index Memberships
Equillium Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #513 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1784 of 3165 |
Weight: Equillium Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Equillium Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Equillium Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.11x
Equillium Inc's market cap is 1.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $64.55 Million | $15.76 Million | -$62.43 Million | 4.10x | N/A |
| 2023 | $44.03 Million | $36.08 Million | -$13.34 Million | 1.22x | N/A |
| 2024 | $45.56 Million | $41.09 Million | -$8.07 Million | 1.11x | N/A |
Competitor Companies of EQ by Market Capitalization
Companies near Equillium Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Equillium Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Equillium Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Equillium Inc's market cap moved from $496.89 Million to $ 126.66 Million, with a yearly change of -22.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $126.66 Million | +34.19% |
| 2025 | $94.38 Million | +107.16% |
| 2024 | $45.56 Million | +3.49% |
| 2023 | $44.03 Million | -31.79% |
| 2022 | $64.55 Million | -71.88% |
| 2021 | $229.57 Million | -29.53% |
| 2020 | $325.78 Million | +58.28% |
| 2019 | $205.82 Million | -58.58% |
| 2018 | $496.89 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Equillium Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $126.05 Million USD |
| MoneyControl | $126.05 Million USD |
| MarketWatch | $126.05 Million USD |
| marketcap.company | $126.05 Million USD |
| Reuters | $126.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as we… Read more